Medicaid Expenditures and Estimated Rebates for Epinephrine Autoinjectors, 2012 to 2016

JAMA Intern Med. 2017 May 1;177(5):734-736. doi: 10.1001/jamainternmed.2017.0257.

Abstract

This study uses publicly available data to estimate the amount of money that Medicaid lost due to the misclassification of brand-name epinephrine autoinjectors as generic products.

MeSH terms

  • Centers for Medicare and Medicaid Services, U.S.
  • Cost of Illness
  • Epinephrine / administration & dosage*
  • Epinephrine / economics
  • Health Expenditures / statistics & numerical data
  • Humans
  • Injections, Intramuscular / economics*
  • Injections, Intramuscular / instrumentation
  • Insurance, Health, Reimbursement / economics*
  • Insurance, Health, Reimbursement / statistics & numerical data
  • Managed Care Programs / economics
  • Medicaid / economics*
  • Medicaid / statistics & numerical data
  • United States

Substances

  • Epinephrine